The union representing around 1,200 academic staff at the Northern Alberta Institute of Technology (NAIT) could soon have the ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines for COVID-19 and shingles, migraine treatments, and blockbuster cancer drugs, according to data ...

Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration ...

The first 10 prescription drugs subject to Medicare price negotiations go into effect on Jan. 1. Medicare beneficiaries will see substantially lower costs for those treatments in 2026, according to a ...

Older adults discharged from hospitals on multiple medications are less likely to regain independence during rehabilitation, a new study suggests. The Japanese study, published in the journal BMC ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The ...

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

Dec. 19 (UPI) --President Donald Trump on Friday announced that nine of the largest drugmakers in the United States and Europe have agreed to voluntarily sell their medications at lower prices in a ...

Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication Ibrance, according to the Centers for Medicare & Medicaid Services (CMS). The ...

More than 11,000 bottles of a common blood pressure medication have been recalled nationwide. Bisoprolol fumarate and hydrochlorothiazide tablets made by Glenmark Pharmaceuticals may contain trace ...

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Elaine Chen covers biotech, ...